论文部分内容阅读
目的观察瑞替普酶与尿激酶用于急性ST段抬高型心肌梗死病人溶栓治疗的有效性及安全性。方法将113例急性ST段抬高型心肌梗死病人随机分为瑞替普酶组(57例)与尿激酶组(56例),观察两组溶栓冠脉血管再通率、心血管事件的发生情况、出血并发症及住院期间死亡情况,比较两种药物溶栓治疗的有效性及安全性。结果瑞替普酶组治疗后30min,1h及2h血管再通率均高于尿激酶组,差异有统计学意义(P<0.01);发病距溶栓时间在6h以内和(6~12)h再通率相比较,瑞替普酶组均高于尿激酶组,差异有统计学意义(P<0.05);两组溶栓后住院期间心血管事件及并发症的发生情况,无统计学意义(P>0.05)。结论瑞替普酶较尿激酶有更高的血管再通率,能够早期快速开通血管,是一种安全有效的溶栓药物。
Objective To observe the efficacy and safety of reteplase and urokinase for thrombolysis in patients with acute ST-segment elevation myocardial infarction. Methods A total of 113 patients with acute ST-elevation myocardial infarction were randomly divided into reteplase group (n = 57) and urokinase group (56 patients). The rate of coronary recanalization, cardiovascular events The occurrence of bleeding complications and death during hospitalization, compared the efficacy and safety of the two drugs in thrombolytic therapy. Results The rate of recanalization at 30 min, 1 h and 2 h after reteplase treatment was significantly higher than that of urokinase (P <0.01). The incidence of recanalization within 6 h and (6-12) h Reperfusion rate, reteplase group were higher than that of urokinase group, the difference was statistically significant (P <0.05); two groups of patients with cardiovascular events and complications during thrombolysis after thrombolytic therapy, no statistically significant (P> 0.05). Conclusion Reteplase has a higher rate of recanalization than urokinase, which can quickly and quickly open the blood vessel. It is a safe and effective thrombolytic drug.